Dr. Sandra Springer will review the national statistics of opioid epidemic and other stimulant epidemics in the United States fueling new HIV/ HCV and bacterial infection epidemics across the country. She will discuss effect of medication treatment of Opioid use disorder (OUD) on improving not only opioid use but also HIV and HCV treatment and prevention. Additionally, she will review the National Academy of Science, Engineering and Medicine’s recent recommendations to integrate OUD and infectious disease prevention and treatment.
Sandra Springer, MD, is an associate professor of medicine in the Department of Internal Medicine, Section of Infectious Diseases (ID) at the Yale School of Medicine. She is also the Director of the ID Clinic at the Newington site and an attending ID physician at the West Haven site of the VA Connecticut Healthcare System. She is board-certified in internal medicine, ID, and addiction medicine. She has significant clinical and research experience with use of medications for the treatment of opioid (OUD) and alcohol use disorders (AUD) among persons living with HIV, persons in the criminal justice system (CJS), and persons in the community in both inpatient and outpatient settings. She has evaluated the effectiveness of buprenorphine (BUP) to reduce opioid relapse and improve HIV viral suppression in persons released from prison and jail with OUD and HIV. She has conducted RCTs and evaluated the impact of extended-release naltrexone (XR-NTX) as a PI for NIAAA and NIDA funded studies among persons in the CJS with HIV and AUD and OUD. She currently is co-leading two NIDA-funded studies evaluating the impact of MOUD on immunobiological outcomes; and on HIV latency and persistence among persons with OUD and HIV. She is also co-PI on 3 other large RCTs including a large VA COOP grant evaluating injectable buprenorphine compared to SL buprenorphine among Veterans with OUD; a NIDA JCOIN grant comparing XR-NTX to injectable BUP for persons in the CJS; and an NCATS grant to evaluate long-acting BUP and integrated ID treatment in persons within the hospital. She is an appointed National Academy of Science committee member that evaluated community programs nationally that integrated OUD and ID treatment; a current member of ASAM’s National Practice Guideline Expert Panel for Medication Treatment for OUD; and current a member of the IDSA and HIVMA Working Group on addressing ID issues in the opioid epidemic. She has presented her work at numerous national and international conferences, and has published over 100 manuscripts, book chapters and abstracts regarding the subject of HIV, CJS and SUDs.
Please click the link below to join the webinar:
https://nyu.zoom.us/j/98519120974
Or Telephone:
US: +1 646 558 8656
Webinar ID: 98519120974